Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02596828
Other study ID # RIST-rPB-2015-P
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2016
Est. completion date April 2021

Study information

Verified date July 2021
Source University of Regensburg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Children, adolescents and young adults with relapsed or treatment refractory pineoblastoma (rPB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not available.


Description:

The multimodal metronomic approach combining molecular targeted drugs (rapamycin and dasatinib) with conventional chemotherapy (irinotecan and temozolomide) will be investigated in a randomized fashion as new treatment strategy for patients with rPB. The intention is to assess the therapeutic benefit of molecular targeted drugs for the treatment of rPB. The combination of irinotecan and temozolomide showed activity in the treatment of several solid organ tumors, brain tumors and neuroblastoma. In one study relapsed neuroblastoma (rNB) patients received a median of 5 courses of 5 days irinotecan and temozolomide every 3 to 4 weeks with a cumulative dose of 35% lower than in the RIST design. 33% had disease regression with 8% CR or PR. A phase II study in rNB also using irinotecan and temozolomide with a substantially lower intensity showed a response rate of 15%. The combination of a mTOR inhibitor with a multi-kinase inhibitor demonstrated in preclinical studies a synergistic effect on cell cycle arrest, apoptosis and sensitization for radio- and chemotherapy. It is assumed that this combination of molecular targeted drugs with a tolerable conventional chemotherapy consisting of irinotecan and temozolomide can substantially improve the outcome of this patient population. A group of 20 rNB patients treated with the RIST therapy approach in a compassionate use setting showed an overall survival of 55% at a median of 80 weeks with a tolerable adverse event profile.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date April 2021
Est. primary completion date April 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 25 Years
Eligibility Inclusion Criteria: Patients with relapsed and refractory high-grade pineoblastome (=rPB) and all of the following criteria will be considered for admission to the clinical trial: - Children, adolescents and young adults 0 months to 25 years - Signed written informed consent (patient or his/her parents/legal guardian) - Females of childbearing age must have a negative urine pregnancy test prior to starting the study drug. The first pregnancy test must be performed within 10-14 days prior to the start of the study drug and the second pregnancy test must be performed within 24 hours prior to the start of study drug. The subject may not receive the study drug until the investigator has verified that the results of these pregnancy tests are negative. - Females of childbearing age must comply with the institutional standards of birth control with a pearl index <1%. Contraception must be started at least four weeks before the start of the investigational therapy. - Females of childbearing age must be willing to abstain from breastfeeding for the duration of the clinical trial and for at least 30 days after discontinuation of the clinical trial. - Males must agree not to father a child and must use latex condom during any sexual contact with women of childbearing age during and for 6 months after therapy ends or is stopped, even if they have undergone successful vasectomy. - Willing and able to complete the clinical trial procedures, as described in the protocol - Non-smoker for at least the previous 3 months. Smoking is not allowed during the entire study period - Abstain from alcohol within the last 24 hours before screening and before admission to the clinical trial center as well as during the entire clinical trial. The regular daily ethanol intake has to be less than 20g/day for at least the previous three months. - Patients are required to have an absolute neutrophil count (ANC) =500/µL, hemoglobin =8g/dL (transfusion permitted), and an unsupported platelet count =30,000/µL unless: - patient is refractory or relapsed early after primary therapy Exclusion Criteria: Patients presenting with any of the following criteria will not be included in this clinical trial: - Pregnancy, nursing - Patients who suffered from a thrombotic event and need anticoagulation (i.e. coumadine derivatives or low molecular weight heparin derivatives, LMWH) - Patients with cardiac arrhythmias especially prolonged QT - Patients with chronic inflammatory bowel diseases and/or bowel obstruction - Patients with bilirubin serum levels 1,5 fold above the upper normal limit - Vaccination with a live virus vaccine during the clinical trial - Impaired liver function and/or impaired renal function (hepatic and renal index parameter two times above normal range; see below) - Potentially unreliable subjects, probably non compliant subjects and those judged by the investigator to be unsuitable for the study - Doubts about the patient's cooperation - Any contraindications or known hypersensitivity to the IMPs or to any of the other components: (see SPC "Fachinformation") - Known allergic reactions to the treatment medication - Patients who were treated with radiation and/or chemotherapy for any other oncological condition - Participation in any other interventional phase I to III trial - Sexually active patients who refuse to use contraception according to the institutional requirements - Patients with extremely poor general condition (Karnofsky or Lansky score <50%) - Neutrophil count (ANC) <500/µL, hemoglobin <8g/dL (transfusion permitted), and an unsupported platelet count <30 000/µL - 12-lead ECG with QTc>500 msec / QTc>60 msec baseline - Patients with hepatitis B reactivation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Temozolomide
Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171). Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
Irinotecan
Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
Dasatinib
Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
Rapamycin
Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally

Locations

Country Name City State
Germany University Hospital of Regensburg Regensburg

Sponsors (1)

Lead Sponsor Collaborator
University of Regensburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is progression-free survival (PFS) According to:
Imaging criteria to
MRI, CT or
CSF evaluations or
date of death of any cause
Time interval from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks
Secondary Overall survival (OS) According to: questionnaire From the first course of the investigational treatment up to the end of the trial assessed to 52 weeks
Secondary Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm According to:
• Imaging criteria to
MRI, CT or
CSF evaluations
From the first course of the investigational treatment up to the end of the trial assessed to 52 weeks
Secondary Duration until adequate response to this treatment regimen According to:
• Imaging criteria to
MRI, CT or
CSF evaluations
From the first course of the investigational treatment up to the end of the trial assessed to 52 weeks
Secondary Assessment of quality of life (Lansky and Karnofsky Scores) According to:
Lansky and Karnofsky Scores
From the first course of the investigational treatment up to the end of the trial assessed to 52 weeks
Secondary Toxicity of this combination of drugs in children, adolescents and young adults with rNB - Assessment according to the latest version of the CTC criteria Assessment according to the latest version of the CTC criteria. In particular due to the expected AE Profile:
Myelosuppressive measures (RBC, PLT units) Infectious complications Gastrointestinal problems
From the first course of the investigational treatment up to the end of the trial assessed to 52 weeks
Secondary Safety and tolerability of the investigational treatment - Assessment according to the latest version of the CTC criteria Assessment according to the latest version of the CTC criteria. In particular due to the expected AE Profile:
Myelosuppressive measures (RBC, PLT units) Infectious complications Gastrointestinal problems
From the first course of the investigational treatment up to the end of the trial assessed to 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT01217437 - Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Phase 2
Completed NCT01884194 - Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging N/A
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Completed NCT02095132 - Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Phase 1/Phase 2
Completed NCT00565903 - Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Completed NCT00179803 - Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Phase 2
Active, not recruiting NCT03638167 - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Phase 1
Active, not recruiting NCT06193759 - Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) Phase 1
Active, not recruiting NCT03500991 - HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Phase 1
Active, not recruiting NCT05934630 - Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Completed NCT00867178 - Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Phase 1
Recruiting NCT03382158 - International PPB/DICER1 Registry
Withdrawn NCT03990597 - StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord Phase 1
Active, not recruiting NCT01063114 - Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma N/A